Delving into the Latest Updates on RO-275 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

HCN1

Action

blockers

Mechanism

HCN1 blockers(hyperpolarization activated cyclic nucleotide gated potassium channel 1 blockers)

Therapeutic Areas

Other Diseases

Active Indication

Cognitive Dysfunction

Inactive Indication-

Originator Organization

Roche Pharma AG

Active Organization

Roche Pharma AG

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC18H14ClN5O

InChIKeySTQKUEFQEVDNLU-UHFFFAOYSA-N

CAS Registry2648837-04-9

Author: Gasser, Rodolfo ; Paina, Manuel ; Weber, Michael ; He, Weiping ; Roberts, Sonia ; Wyler, Roger ; Gundlfinger, Anja ; Reutlinger, Michael ; Rolland, Jean-Francois ; Waiz, David ; Schnider, Patrick ; O′Connor, Eoin C. ; Greiter-Wilke, Andrea ; Haab, Rachel ; Hierl, Markus ; Hall, Benjamin J. ; Bartels, Bjorn ; Dupont, Amanda ; Harde, Eva ; Wach, Jean-Yves

Hyperpolarization-activated and cyclic-nucleotide-gated 1 (HCN1) ion channels are proposed to be critical for cognitive function through regulation of synaptic integration.However, resolving the precise role of HCN1 in neurophysiol. and exploiting its therapeutic potential has been hampered by minimally selective antagonists with poor potency and limited in vivo efficiency.Using automated electrophysiol. in a small-mol. library screen and chem. optimization, we identified a primary carboxamide series of potent and selective HCN1 inhibitors with a distinct mode of action.In cognition-relevant brain circuits, selective inhibition of native HCN1 produced on-target effects, including enhanced excitatory postsynaptic potential summation, while administration of a selective HCN1 inhibitor to rats recovered decrement working memory.Unlike prior non-selective HCN antagonists, selective HCN1 inhibition did not alter cardiac physiol. in human atrial cardiomyocytes or in rats.Collectively, selective HCN1 inhibitors described herein unmask HCN1 as a potential target for the treatment of cognitive dysfunction in brain disorders.

100 Deals associated with RO-275

Login to view more data